Clinical Trial Update: CAR-pNK Cell Immunotherapy in MUC1 Positive Relapsed or Refractory Solid Tumor [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial evaluating CAR-pNK cell immunotherapy for MUC1-positive relapsed or refractory solid tumors; current status is not provided.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Gastric Cancer
• Hepatocellular Carcinoma
• Malignant Glioma
• Non-small Cell Lung Cancer
• Pancreatic Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• CAR-pNK Cell Immunotherapy

Snippet

Sponsor: PersonGen BioTherapeutics (Suzhou) Co., Ltd. | Conditions: Hepatocellular Carcinoma, Non-small Cell Lung Cancer | Phase 1, Phase 2 | Status: UNKNOWN